DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Goldstein DA, Gordon N, Davidescu M. et al.
A phamacoeconomic analysis of personalized dosing vs fixed dosing of pembrolizumab in firstline PD-L1-positive non-small cell lung cancer.
J Natl Cancer Inst 2017;109(11).
We do not assume any responsibility for the contents of the web pages of other providers.